EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin in Obese Pregnancy: Developmental Reprogramming of Offspring Liver and MASLD Risk by Age and Sex

Elena Müller-Limberger iD, Bettina Frederick, Sebastian Hansen, Maria Wohlfarth, Philipp Kasper iD, Ruth Janoschek iD, Esther Mahabir iD, Pascal Fischer, Andrea Mesaros, Martin Purrio, Alexander Quaas iD, Miguel A Alejandre Alcázar iD und 3 weitere

Endocrinology · 2026

DOI: 10.1210/endocr/bqaf188 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2026. Verfasst von Elena Müller-Limberger und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne 50937, Germ…. Hauptthemen laut MEDLINE: Metformin, Liver, Prenatal Exposure Delayed Effects, Pregnancy in Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Maternal obesity before and during pregnancy causes maladaptive fetal development with long-term effects on offspring's metabolic health, including a higher risk of metabolic dysfunction-associated steatotic liver disease. Treatment with metformin during obese pregnancy has been suggested to prevent adverse fetal programming, but its long-term effects on offspring liver metabolism remain uncertain. In wild-type C57BL/6NCrl mice, obesity was induced by feeding a high-fat/high-sucrose Western-style diet before and throughout gestation and lactation. A subset of obese dams received metformin during gestation. Offspring from control, obese (OB), and obese with metformin-treated (OB + M) dams were analyzed at postnatal days (P) 21 and 56 for their metabolic phenotype, hepatic histomorphology, and key metabolic proteins. At P21, maternal metformin treatment worsened obesity-related traits in male OB + M offspring, including increased body weight, length, and fat volume, higher plasma leptin, insulin, and resistin levels, and impaired glucose tolerance. Female OB + M offspring also showed a worsening of obesity traits, though less pronounced. Hepatic lipid accumulation displayed sex-specific patterns; male OB + M offspring exhibited reduced lipid accumulation, whereas female OB + M offspring demonstrated increased lipid accumulation. By P56, phenotypic parameters returned to normal, but molecular alterations persisted, involving shifts in hepatic fatty acid metabolism and mitochondrial respiratory chain complexes. Maternal metformin during obese pregnancy has age- and sex-specific effects on offspring, aggravating early obesity traits in a sex-dependent manner and prompting adaptations in hepatic metabolism during adolescence. These findings highlight the controversy surrounding metformin use during obese pregnancy, given its potential to induce sex-specific obesity and metabolic disturbances in offspring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminLiverPrenatal Exposure Delayed EffectsPregnancy in ObesityHypoglycemic AgentsObesityAnimalsPregnancyFemaleMaleMiceMice, Inbred C57BLLipid MetabolismSex FactorsDiet, High-FatFetal Development

Stichwörter der Autor:innen

MASLDchildhood obesityhepatic steatosismaternal obesitymetabolic programmingmetformin

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Paediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne 50937, Germany.
  • Department of Gastroenterology and Hepatology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne 50937, Germany.
  • Comparative Medicine, Center for Molecular Medicine Cologne (CMMC), Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne 50931, Germany.
  • Phenotyping Core Facility, Max Planck Institute for Biology of Ageing, Cologne 50931, Germany.
  • Department of Pathology, Faculty of Medicine and University Hospital of Cologne, University of Cologne, Cologne 50937, Germany.

ORCID-Profile: Elena Müller-Limberger, Philipp Kasper, Ruth Janoschek, Esther Mahabir, Alexander Quaas, Miguel A Alejandre Alcázar, Jörg Dötsch, Eva Hucklenbruch-Rother, Sarah Appel

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Müller-Limberger, E., Frederick, B., Hansen, S., Wohlfarth, M., Kasper, P., Janoschek, R., Mahabir, E., Fischer, P., Mesaros, A., Purrio, M., Quaas, A., Alejandre Alcázar, M. A., Dötsch, J., Hucklenbruch-Rother, E., & Appel, S. (2026). Metformin in Obese Pregnancy: Developmental Reprogramming of Offspring Liver and MASLD Risk by Age and Sex. Endocrinology. https://doi.org/10.1210/endocr/bqaf188

Vancouver

Müller-Limberger E, Frederick B, Hansen S, Wohlfarth M, Kasper P, Janoschek R, et al. Metformin in Obese Pregnancy: Developmental Reprogramming of Offspring Liver and MASLD Risk by Age and Sex. Endocrinology. 2026. doi:10.1210/endocr/bqaf188

BibTeX
@article{MllerLimberger2026,
  author = {Müller-Limberger, Elena and Frederick, Bettina and Hansen, Sebastian and Wohlfarth, Maria and Kasper, Philipp and Janoschek, Ruth and Mahabir, Esther and Fischer, Pascal and Mesaros, Andrea and Purrio, Martin and Quaas, Alexander and Alejandre Alcázar, Miguel A and Dötsch, Jörg and Hucklenbruch-Rother, Eva and Appel, Sarah},
  title = {Metformin in Obese Pregnancy: Developmental Reprogramming of Offspring Liver and MASLD Risk by Age and Sex},
  journal = {Endocrinology},
  year = {2026},
  doi = {10.1210/endocr/bqaf188}
}
Kostenlos starten →